TY - JOUR
T1 - SOHO State of the Art Update and Next Questions
T2 - Advances in the Treatment of Adult Acute Lymphoblastic Leukemia
AU - Paul, Shilpa
AU - Rausch, Caitlin R.
AU - Welch, Mary Alma
AU - Kantarjian, Hagop M.
AU - Jabbour, Elias J.
N1 - Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/8
Y1 - 2019/8
N2 - The treatment of adult acute lymphoblastic leukemia (ALL) has largely followed the successful pediatric model that uses multi-agent chemotherapy regimens. Although cytotoxic chemotherapy can induce complete remissions, elderly patients are frequently unable to tolerate its intensity owing to toxicities and comorbidities. Elderly patients particularly often relapse, leading to a 5-year overall survival (OS) of only 20%. In an effort to improve outcomes while minimizing toxicities, novel targeted therapies have been developed: monoclonal antibodies against CD19, CD20, and CD22; tyrosine kinase inhibitors; chimeric antigen receptor T-cell therapies; and BH3 mimetics. Here, we discuss advancements in the treatment of ALL and their places in the armamentarium for adult patients.
AB - The treatment of adult acute lymphoblastic leukemia (ALL) has largely followed the successful pediatric model that uses multi-agent chemotherapy regimens. Although cytotoxic chemotherapy can induce complete remissions, elderly patients are frequently unable to tolerate its intensity owing to toxicities and comorbidities. Elderly patients particularly often relapse, leading to a 5-year overall survival (OS) of only 20%. In an effort to improve outcomes while minimizing toxicities, novel targeted therapies have been developed: monoclonal antibodies against CD19, CD20, and CD22; tyrosine kinase inhibitors; chimeric antigen receptor T-cell therapies; and BH3 mimetics. Here, we discuss advancements in the treatment of ALL and their places in the armamentarium for adult patients.
KW - Blinatumomab
KW - Chimeric antigen receptor T-cell therapy
KW - Inotuzumab ozogamicin
KW - Monoclonal antibodies
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85068758006&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068758006&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2019.06.011
DO - 10.1016/j.clml.2019.06.011
M3 - Review article
C2 - 31307896
AN - SCOPUS:85068758006
SN - 2152-2650
VL - 19
SP - 471
EP - 479
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 8
ER -